Mithra Pharmaceuticals
Bankruptcy closedMithra Pharmaceuticals was declared bankrupt on 10-06-2024 (Tribunal de l’entreprise de Liège, division Liège); according to the publications in the Belgian State Gazette the procedure is no longer open (latest notice 03-07-2024). The 2022 annual accounts show equity of €290.23M and a net result of €-42.54M.
Signals
Four signals. The signal on the left, the evidence on the right.
+raises risk○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2022 was due by 31-07-2023 and was filed on 12-06-2023, 49 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
not confirmed
2024
not filed
2023
not filed
2022
49 d early
2021
37 d early
2020
46 d early
2019
31 d early
← before the deadline
after the deadline →
Financials · fiscal year 2022, full schema, statutory
Turnover
€23.28M▲ 48.5%
2021 · €15.68M
2018: €49.79M
2019: €12.84M
2020: €16.68M
2021: €15.68M
2018 → 2022
EBIT margin
-1.9%▼ 13.4pp
2021 · 11.5%
2018: -30.1%
2019: 3.5%
2020: 6.3%
2021: 11.5%
2018 → 2022
Net result
€-42.54M▼ 4,713%
2021 · €-884k
2018: €-14.38M
2019: €-34.73M
2020: €-21.30M
2021: €-884k
2018 → 2022
Working capital
€105.46M▼ 59.4%
2021 · €259.73M
2018: €105.30M
2019: €102.79M
2020: €268.01M
2021: €259.73M
2018 → 2022
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20182019202020212022Trend
Turnover€49.79M-€12.84M▼ 74.2%€16.68M▲ 30.0%€15.68M▼ 6.0%€23.28M▲ 48.5%
Equity€190.42M-€194.73M▲ 2.3%€241.54M▲ 24.0%€249.88M▲ 3.5%€290.23M▲ 16.1%
Operating result€-15.01M-€450k€1.06M▲ 135%€1.81M▲ 71.2%€-439k
Net result€-14.38M-€-34.73M▼ 141%€-21.30M▲ 38.7%€-884k▲ 95.9%€-42.54M▼ 4,713%
Result per fiscal year
Operating resultNet result
The operating result turns negative in 2022: a loss of €439k after €1.81M in 2021.
Balance-sheet composition
2022 in colour, 2021 as the grey bar beneath
Assets €513.65M
Fixed assets
€356.71M▲ 138%
Current assets
€156.94M▼ 49.4%
Equity and liabilities €513.65M
Equity
€290.23M▲ 16.1%
Provisions
€266k=
Debt
€223.15M▲ 6.3%
The debt ratio falls from 45.6% to 43.4%: equity grows faster than debt.
Key figures and ratios
EBITDA
€94k▼
2021 · €2.41M
Cash flow
€-42.01M▼
2021 · €-283k
Solvency
56.5%▲
2021 · 54.3%
Current ratio
3.05▼
2021 · 6.15
Quick ratio
3.05▼
2021 · 6.15
Debt / equity
0.77▼
2021 · 0.84
ROE
-14.7%▼
2021 · -0.4%
ROA
-8.3%▼
2021 · -0.2%
Interest coverage
0.01▼
2021 · 0.34
Debt
€223.15M▲
2021 · €209.92M
Debt ≤ 1 year
€51.48M▲
2021 · €50.38M
Debt > 1 year
€169.54M▲
2021 · €159.27M
Income taxes
€2.58M▲
2021 · €12k
Staff costs
€4.02M▲
2021 · €3.22M
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2022 against 2021
Balance sheet
Code20212022
Assets
Total assets20/58€460.07M€513.65M▲
Fixed assets21/28€149.96M€356.71M▲
Intangible fixed assets21€1.25M€1.00M▼
Tangible fixed assets22/27€1.72M€1.36M▼
Land and buildings22€857k€775k▼
Plant, machinery and equipment23€314k€105k▼
Furniture and vehicles24€519k€428k▼
Assets under construction and advance payments27€29k€52k▲
Financial fixed assets28€146.99M€354.35M▲
Affiliated companies280/1€146.97M€354.33M▲
Participating interests280€146.97M€354.33M▲
Other financial fixed assets284/8€17k€17k=
Shares284€15k€15k=
Amounts receivable and cash guarantees285/8€2k€2k=
Current assets29/58€310.11M€156.94M▼
Amounts receivable after more than one year29€55k€43k▼
Other amounts receivable291€55k€43k▼
Amounts receivable within one year40/41€289.43M€126.53M▼
Trade receivables40€8.41M€13.97M▲
Other amounts receivable41€281.02M€112.56M▼
Cash at bank and in hand54/58€17.04M€27.60M▲
Deferred charges and accrued income490/1€3.59M€2.76M▼
Equity and liabilities
Total equity and liabilities10/49€460.07M€513.65M▲
Equity10/15€249.88M€290.23M▲
Contributions10/11€370.84M€453.74M▲
Capital10€32.25M€41.23M▲
Issued capital100€32.25M€41.23M▲
Outside capital11€338.59M€412.51M▲
Share premium1100/10€338.59M€412.51M▲
Reserves13€598k€598k=
Non-distributable reserves130/1€598k€598k=
Legal reserve130€598k€598k=
Profit (loss) carried forward14€-121.56M€-164.10M▼
Provisions and deferred taxes16€266k€266k=
Provisions for liabilities and charges160/5€266k€266k=
Environmental obligations163€266k-
Other liabilities and charges164/5-€266k
Amounts payable17/49€209.92M€223.15M▲
Amounts payable after more than one year17€159.27M€169.54M▲
Financial debts170/4€129.27M€144.54M▲
Unsubordinated bonds171€125.00M€90.90M▼
Credit institutions173€2.76M€2.01M▼
Other loans174€1.52M€51.63M▲
Other amounts payable178/9€30.00M€25.00M▼
Amounts payable within one year42/48€50.38M€51.48M▲
Current portion of amounts payable after more than one year42€6.18M€11.09M▲
Financial debts43€32.00M€26.00M▼
Credit institutions430/8€32.00M€26.00M▼
Trade debts44€1.73M€2.23M▲
Suppliers440/4€1.73M€2.23M▲
Taxes, remuneration and social security45€238k€2.67M▲
Taxes450/3-€2.08M
Remuneration and social security454/9€238k€590k▲
Other amounts payable47/48€10.24M€9.48M▼
Accrued charges and deferred income492/3€266k€2.13M▲
Income statement
Code20212022
Operating income70/76A€15.86M€23.56M▲
Turnover70€15.68M€23.28M▲
Other operating income74€178k€280k▲
Non-recurring operating income76A-€6k
Operating charges60/66A€14.05M€24.00M▲
Goods for resale, raw materials and consumables60€142k€83k▼
Purchases600/8€130k€83k▼
Change in stocks: decrease (increase)609€13k-
Services and other goods61€10.04M€19.23M▲
Remuneration, social security and pensions62€3.22M€4.02M▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€601k€533k▼
Other operating charges640/8€43k€131k▲
Non-recurring operating charges66A-€9k
Operating profit (loss)9901€1.81M€-439k▼
Financial income75/76B€4.82M€27.40M▲
Recurring financial income75€4.45M€22.29M▲
Income from current assets751€4.45M€22.28M▲
Other financial income752/9€4k€10k▲
Non-recurring financial income76B€366k€5.12M▲
Financial charges65/66B€7.50M€66.93M▲
Recurring financial charges65€7.15M€10.27M▲
Debt charges650€7.12M€10.22M▲
Other financial charges652/9€33k€45k▲
Non-recurring financial charges66B€345k€56.66M▲
Profit (loss) for the period before taxes9903€-872k€-39.96M▼
Income taxes67/77€12k€2.58M▲
Taxes670/3€12k€2.58M▲
Profit (loss) for the period9904€-884k€-42.54M▼
Profit (loss) for the period to be appropriated9905€-884k€-42.54M▼
Appropriation of the result
Profit (loss) to be appropriated9906€-121.56M€-164.10M▼
Profit (loss) brought forward from the previous period14P€-120.68M€-121.56M▼
Social balance
Average headcount (FTE)908741.040.0▼
The notes to these accounts (97 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2024
03-07
Bankruptcy
Judicial dissolution
Ondernemingsrechtbank Antwerpen, afdeling Hasselt · van: MITHRA PHARMACEUTICALS NV- RUE SAINT-GEORGES 5, 4000 LIEGE1
14-06
Bankruptcy
Opening
Tribunal de l’entreprise de Liège, division Liège · MITHRA PHARMACEUTICALS SA RUE SAINT-GEORGES 5, 4000 LIEGE 1 · event 10-06-2024
2023
13-06
NBB filing
Annual accounts filed
fiscal year 2022 · consolidated
12-06
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
31-12
Financial
Weakest financial yearnet €-42.54M
Net result drops to €-42.54M, the lowest in the series.
31-12
Financial
Equity above €250MEq €290.23M ▲16.1%
Equity rises from €249.88M to €290.23M.
24-06
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
24-06
NBB filing
Annual accounts filed
fiscal year 2021 · consolidated
2021
15-06
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
15-06
NBB filing
Annual accounts filed
fiscal year 2020 · consolidated
2020
30-06
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
30-06
NBB filing
Annual accounts filed
fiscal year 2019 · consolidated
2019
31-12
Financial
Liquidity quadruplescurrent ratio 10.09
Current ratio from 2.63 to 10.09; short-term debt falls from €64.42M to €11.31M.
24-06
NBB filing
Annual accounts filed
fiscal year 2018 · consolidated
21-06
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2017
28-07
State Gazette act
General meeting · Capital increase
Capital · Statutes amendment
30-01
State Gazette act
Incorporation · Founding capital
Corporate purpose · General meeting
2013
12-04
State Gazette act
General meeting · Purpose change
Statutes amendment · Capital
12-04
State Gazette act
General meeting · Purpose change
Capital increase · Capital
SignalFinancial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
58 directors, no change since 2024
C2M4E SRL
CurrentDirector · since 10-04-2024 · Legal entity
CMM&C SRL
CurrentCo ceo · since 10-04-2024 · Legal entity
Xavier Paoli
CurrentCo ceo · since 10-04-2024
Bronzet Management
CurrentDaily management delegate · since 07-12-2023
Gaudeto SRL
CurrentAdministrateur indépendant · since 07-12-2023 · Legal entity
Inge Beernaert
CurrentDirector · since 07-12-2023
+ 30 not shown in this overview
10-04-2024
C2M4E SRL: Appointed as Director
10-04-2024
CMM&C SRL: Appointed as Co ceo
10-04-2024
Xavier Paoli: Appointed as Co ceo
10-04-2024
Castors Development SA: Resigned as Director
10-04-2024
CEO: Resigned as Directeur général
07-12-2023
Bronzet Management: Appointed as Daily management delegate
07-12-2023
Gaudeto SRL: Appointed as Administrateur indépendant
07-12-2023
Gaudeto SRL: Resigned as Administrateur indépendant
07-12-2023
Inge Beernaert: Resigned as Director
07-12-2023
Inge Beernaert: Appointed as Director
07-12-2023
Inge Beernaert: Appointed as Administrateur indépendant
07-12-2023
Inge Beernaert: Resigned as Administrateur indépendant
07-12-2023
Life Science Strategy Consulting SRL: Appointed as Administrateur indépendant
07-12-2023
Life Science Strategy Consulting SRL: Resigned as Administrateur indépendant
07-12-2023
Ribono SRL: Appointed as Administrateur indépendant
07-12-2023
Ribono SRL: Resigned as Administrateur indépendant
07-12-2023
Alius Modi SRL: Appointed as Director
07-12-2023
Eva Consulting SRL: Appointed as Director
07-12-2023
Castors Development SA: Appointed as Administrateur indépendant
07-12-2023
David Horn Solomon: Resigned as Daily management delegate
28-06-2023
David H. Solomon: Appointed as Daily management delegate
28-06-2023
Leon Van Rompay: Resigned as Daily management delegate
06-01-2023
Christophe Pelzer: Appointed as Representant permanent commissaire
06-01-2023
Cédric Antonelli: Resigned as Representant permanent commissaire
+ 61 not shown in this overview
Location & real-estate footprint
Registered office, Liège · 2 establishment units since 1999
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue Saint-Georges 54000 LiègeGround area
126 m²
Building footprint
43 m²
Volume, LiDAR
649 m³
Parcel 62810C0909/00G000, Wallonia · tallest building 16.9 m, ±5 floors. Linked by address, not a title deed.
2 establishment units
Rue Saint-Georges 5, 4000 Liège
since 19992.092.982.955
Mithra Pharmaceuticals
since 20172.266.367.683
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62810C0909/00G000 | Wallonia | 126 m² | 1 · 43 m² | 16.9 m · 5 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Statutory auditor
2 auditors| BDO Réviseurs d'entreprises SCRLCurrent Commissaire | 09-09-2021 → present |
Show 1 earlier auditors
| BDO Réviseurs d'entreprises Commissaire succeeded by BDO Réviseurs d'entreprises SCRL in 2021 | 29-08-2018 → 09-09-2021 |
Insolvency mandates
2 mandates| Role | Name | Tenure |
|---|---|---|
| Curator | YVES GODFROID RUE DES AUGUSTINS 32,
4000 LIEGE 1 |
10-06-2024 → present |
| Curator | FRANCOIS MINON RUE DES AUGUSTINS 32, 4000 LIEGE 1- francois.minon@henry-
mersch.be |
10-06-2024 → present |
Structure & network
Connections & network
1 connected companyNetwork connections
Shared director
→
Ownership & control
2 partiesMithra PharmaceuticalsBE 0466.526.646
controls
Where this company holds controlthis company sits on their board2
3 subsidiaries · 1 location
1 location
Group per the LEI register
1 subsidiarySubsidiary:ESTETRA
Recognitions · licences · registrations
Food safety, FASFC
1 siteLiège2.092.982.955
Legal Entity Identifier
5493002FDD273HTEKK14
Similar companies · same sector, comparable size
Organon Heist
BE 0412.581.481
Heist-op-den-Berg · Eq €217.06M
LABORATOIRES S.M.B.
BE 0418.956.361
Sint-Jans-Molenbeek · Eq €212.90M
BAXALTA BELGIUM MANUFACTURING
BE 0563.700.454
Lessines · Eq €533.78M
Pfizer
BE 0401.994.823
Elsene · Eq €155.73M
VISION HEALTHCARE
BE 0685.849.188
Wevelgem · Eq €122.56M
Of 149 companies in sector 21201 we hold annual accounts for 116. 18 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPublic limited company
Founded13-07-1999
Fiscal year end31-12
Activities, NACEBEL
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
46499Wholesale of other household goods
51478
Sources
Crossroads Bank for EnterprisesNational Bank · 31 filingsAddress and cadastre registers
Data from official sources, last processed on 12-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
General meetings
8 convocationsExtraordinary general meeting
de l’assemblée générale extraordinaire mentionnée ci-après n’est pas atteint, une deuxième assemblée générale extraordi- naire se tiendra
Extraordinary general meeting
de la seconde assemblée générale extraordinaire mentionnée ci-après n’est pas atteint, une deuxième assemblée générale extraordi- naire se tiendra
Extraordinary general meeting
Agenda
détaillé ci-après : A) Assemblée générale ordinaire 1. Revue du rapport annuel 2020, en ce compris du rapport de gestion 2020 2. Revue des comptes annuels consolidés clôturés au 31 décembre 2020 3. Revue du rapport du commissaire concernant les comptes annuels consolidés et statutaires clôturés au 31 décembre 2020 4. Revue et approbation des comptes annuels statutaires clôturés au 31 décembre 2020 Proposition de décision : l’assemblée générale approuve les comptes annuels statutaires clôturés au 31 décembre 2020. 5. Affectation du résultat de l’exercice social clôturé au 31 décembre 2020 Proposition de décision : l’assemblée générale approuve l’affectation du résultat de l’exercice social 20 ...
Extraordinary general meeting
Agenda
suivant : Assemblée générale extraordinaire du vendredi 29 novembre 2019 1. Capital autorisé 1.1. Prise de connaissance du rapport spécial établi par le conseil d’administration relatif au renouvellement des pouvoirs dans le cadre du capital autorisé, établi conformément à l’article 604 du Code des sociétés; 1.2. Pouvoir général au conseil d’administration d’augmenter le capital social; Proposition de décision : L’assemblée générale des actionnaires décide,
Extraordinary general meeting
Agenda
suivant : A) Assemblée générale ordinaire 1. Revue du rapport annuel 2018, en ce compris du rapport de gestion 2018. 2. Revue des comptes annuels consolidés clôturés au 31 décembre 2018. 3. Revue et approbation des comptes annuels statutaires clôturés au 31 décembre 2018. Proposition de décision : l’assemblée générale approuve les comptes annuels statutaires clôturés au 31 décembre 2018. 4. Affectation du résultat de l’exercice social clôturé le 31 décembre 2018. Proposition de décision : l’assemblée générale approuve l’affectation du résultat de l’exercice social 2018. 5. Revue du rapport du commissaire concernant les comptes annuels consolidés et statutaires clôturés au 31 décembre 2018. 6 ...
Show 3 more convocations
Extraordinary general meeting
Agenda
suivant : 1. Rapports – Plan de Warrants de 2018 Communication et discussion du : (a) rapport spécial du conseil d’administration de la Société établi conformément aux articles 583, 596 et 598 du Code des sociétés, relatif à la proposition du conseil d’administration de la Société d’émettre un maximum de 1.881.974 warrants (les « Warrants ») en vue de permettre à la Société de les octroyer ultérieurement à certaines personnes liées à la Société par un contrat de travail, un contrat de consultance ou un contrat de management conclu avec la Société ou une de ses filiales, ou par un mandat au sein du conseil d’administration ou d’autres organes de la Société ou une de ses filiales (les « Partic ...
Ordinary general meeting
Agenda
1. Nazicht van het jaarverslag 2017, met inbegrip van het beheers- verslag 2017 2. Nazicht en goedkeuring van het remuneratieverslag afgesloten op 31 december 2017 Voorstel tot besluit : De Algemene Vergadering keurt het remunera- tieverslag goed over het boekjaar afgesloten op 31 december 2017. 3. Nazicht van het verslag van de commissaris betreffende de geconsolideerde jaarrekening afgesloten op 31 december 2017 4. Nazicht van het verslag van de commissaris betreffende de jaar- rekening afgesloten op 31 december 2017 5. Nazicht en goedkeuring van de geconsolideerde en niet- geconsolideerde jaarrekening afgesloten op 31 december 2017 Voorstel tot besluit : De Algemene Vergadering keurt de g ...
Ordinary general meeting
Agenda
suivant : 1. Rapport de gestion du Conseil d’Administration sur les comptes annuels relatifs à l’exercice social clôturé le 31 décembre 2016 2. Approbation du rapport de rémunération